Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM

First Page		Document Content
Date: 2016-06-15 08:00:16 Peptide hormones Recombinant proteins Specialty drugs Biotechnology Monoclonal antibodies Trastuzumab Biocon Insulin glargine Insulin Biosimilar Pharmaceutical industry in India Biopharmaceutical		Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM Add to Reading List Source URL: www.biocon.com Download Document from Source Website File Size: 682,45 KB Share Document on Facebook

	Biotechnology, BS "DBEFNJD.BQ 5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT DocID: 1xTqy - View Document
	PDF Document DocID: 1wroO - View Document
	Building A Better Mousetrap: Patenting Biotechnology In The European Community DocID: 1vr7C - View Document
	BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod DocID: 1vq6b - View Document
	Biotechnology Consultation Agency Response Letter BNF DocID: 1vpUZ - View Document